Affordable Access

Publisher Website

Potential mechanisms of resistance to cytarabine in AML patients

Authors
Journal
Leukemia Research
0145-2126
Publisher
Elsevier
Publication Date
Volume
26
Issue
7
Identifiers
DOI: 10.1016/s0145-2126(01)00184-9
Keywords
  • Drug Resistance
  • Cytarabine
  • 5′-Nucleotidase
  • Acute Myeloid Leukemia
  • Antineoplastic Agents
  • Antimetabolites
Disciplines
  • Medicine

Abstract

Abstract To determine whether the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytoplasmic 5′-nucleotidase (5NT), cytidine deaminase (CDD), topoisomerase I (TOPO I) and topoisomerase II α (TOPO II) are involved in clinical resistance to cytarabine (ara-C), we analyzed the level of expression of these parameters by reverse transcriptase polymerase chain reaction (rt-PCR), at diagnosis in the blast cells of 77 acute myeloid leukemia (AML) patients treated with ara-C, including 31 for whom samples were collected at first relapse. By univariate and/or multivariate analyses, patients with expression of 5NT or hENT1 deficiency at diagnosis had significantly shorter disease-free survival (DFS) and overall survival (OS). These results suggest that expression of 5NT and reduced hENT1 in leukemic blasts at diagnosis are correlated with clinical outcome and may play a role in resistance mechanisms to ara-C in patients with AML.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Mechanisms of drug resistance in AML.

on Cancer Treatment and Research 2002

Cytarabine and clofarabine after high-dose cytarab...

on American Journal of Hematology December 2012

High-dose cytarabine produces high cure rate in so...

on Oncology (Williston Park, N.Y.... February 1999
More articles like this..